Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Moderna, Inc.
< Previous
1
2
3
4
5
Next >
IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program
Today 7:00 EDT
From
Moderna, Inc.
Via
AccessWire
Tickers
MRNA
Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day
May 17, 2022
From
Moderna, Inc.
Via
AccessWire
Tickers
MRNA
Moderna to Host Annual Science and Technology Day on May 17, 2022
May 09, 2022
From
Moderna, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Tickers
MRNA
Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates
May 04, 2022
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Tickers
MRNA
Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union
April 29, 2022
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Tickers
MRNA
Moderna Finalizes Plan for Long-Term Strategic Partnership with The Government of Canada
April 29, 2022
From
Moderna, Inc.
Via
AccessWire
Tickers
MRNA
Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age
April 28, 2022
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Tickers
MRNA
Arpa Garay Joins Moderna as Chief Commercial Officer
April 27, 2022
From
Moderna, Inc.
Via
AccessWire
Tickers
MRNA
Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform
April 19, 2022
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Tickers
MRNA
Moderna to Report First Quarter Financial Results on Wednesday, May 4, 2022
April 13, 2022
From
Moderna, Inc.
Via
AccessWire
Tickers
MRNA
Jorge Gomez Joins Moderna as Chief Financial Officer
April 11, 2022
From
Moderna, Inc.
Via
AccessWire
Tickers
MRNA
Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates
April 11, 2022
From
Moderna, Inc.
Via
AccessWire
Tickers
MRNA
IAVI and Moderna Partner to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies
April 07, 2022
From
Moderna, Inc.
Via
AccessWire
Topics
Death
Exposures
COVID-19
Death
Tickers
MRNA
Moderna Launches New Charitable Foundation
April 04, 2022
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Tickers
MRNA
Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273
March 29, 2022
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
MRNA
Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day
March 24, 2022
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
MRNA
Moderna Finalizes Strategic Partnership with Australian Government
March 23, 2022
From
Moderna, Inc.
Via
AccessWire
Tickers
MRNA
Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint
March 23, 2022
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
MRNA
Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna's COVID-19 Booster Vaccine
March 21, 2022
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Tickers
MRNA
Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.
March 17, 2022
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
MRNA
Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years)
March 17, 2022
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Tickers
MRNA
Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna's COVID-19 Booster Vaccine
March 16, 2022
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Tickers
MRNA
Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine
March 14, 2022
From
Moderna, Inc.
Via
AccessWire
Tickers
MRNA
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate
March 10, 2022
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Tickers
MRNA
Moderna to Host Third Annual Virtual Vaccines Day on March 24, 2022
March 10, 2022
From
Moderna, Inc.
Via
AccessWire
Tickers
MRNA
Moderna Announces Its Global Public Health Strategy
March 07, 2022
From
Moderna, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Tickers
MRNA
Moderna Announces Memorandum of Understanding with the Government of the Republic of Kenya to Establish its First mRNA Manufacturing Facility in Africa
March 07, 2022
From
Moderna, Inc.
Via
AccessWire
Tickers
MRNA
Moderna Announces Establishment of Enterprise Solutions Hub in Atlanta, Georgia
March 03, 2022
From
Moderna, Inc.
Via
AccessWire
Tickers
MRNA
Moderna to Present at Upcoming Conferences in March 2022
March 02, 2022
From
Moderna, Inc.
Via
AccessWire
Tickers
MRNA
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union
February 24, 2022
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Tickers
MRNA
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.